Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in patients with recurrent high-grade glioma. This study is designed to evaluate the anti-tumor activity of ANG1005 as a new approach to treating primary brain cancers including recurrent glioblastoma multiforme (GBM) and anaplastic glioma. This Phase 2 clinical study follows a previously completed Phase 1 study of ANG1005 in patients with recurrent glioma in which promising signs of anti-tumor activity were observed.
"We are excited to advance ANG1005 into further clinical development for primary brain cancer," said Jean-Paul Castaigne, MD, CEO of Angiochem. "There is a significant unmet need for innovative new treatments for recurrent gliomas such as GBM, one of the most common and most aggressive forms of primary brain cancer. In preclinical and early clinical studies, ANG1005 has demonstrated the ability to cross the blood brain barrier, offering the potential for significant benefit to this patient population with a very challenging cancer."
This Phase 2 clinical study is designed to evaluate the anti-tumor activity of ANG1005 in up to 83 patients with recurrent high-grade glioma at approximately 10 U.S. clinical sites. Study endpoints include objective response rate, progression-free survival and median overall survival, in addition to safety and tolerability. For more information about the study please refer to www.clinicaltrials.gov.
Innovative urine test could improve pancreatic cancer survival rates